Parasitology Research

, Volume 112, Issue 4, pp 1523–1527 | Cite as

Biological assay of a novel quinoxalinone with antimalarial efficacy on Plasmodium yoelii yoelii

  • Norma Rivera
  • Yovani Marrero Ponce
  • Vicente J. Arán
  • Cecilia Martínez
  • Filiberto Malagón
Original Paper


Compound 1-methyl-7-nitro-4-(5-(piperidin-1-yl)pentyl)-3,4-dihydroquinoxalin-2(1H)-one (VAM2-6) was evaluated against a blood-induced infection with chloroquine-sensitive Plasmodium yoelii yoelii lethal strain in CD1 mice in a 4-day test scheme. LD50 of the compound was 56.51 mg/kg and LD10 was 20.58 mg/kg (taken as the highest dose). Animals were treated by oral gavage of 20, 10, and 5 mg/kg. Mice in the untreated control group showed a progressively increasing parasitemia leading to mouse death on 6 days post-infection; in this group, all mice showed parasites in the blood on the fifth day of sampling; the mean parasitemia on that day was 19.4 %. A 4-day dosage of 20 mg/kg of VAM2-6 showed a 97 % chemosuppression of total parasitemia on the fifth day, a 28 days survival time, and 20 % of cured animals. A 4-day dosage of 10 and 5 mg/kg showed 85 and 37 %, respectively, chemosuppression of total parasitemia on the fifth day; but all mice died from days 6 to 9 post-infection with increasing parasitemia. Mice treated with chloroquine at 5 mg/kg survived during the experiment. The results obtained in this study showed that the infection outcome of P. yoelii yoelii-infected mice is affected by VAM2-6 compound by slowing down the parasite replication, retarding the patency time, and increasing their survival time. Although compound VAM2-6 was active at higher doses than chloroquine, these results leaves a door open to the study of its structure in order to improve its antimalarial activity.


Malaria Quinoline Chloroquine Antimalarial Drug Quinoxaline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This research was partially supported by Department of Microbiology and Parasitology, Faculty of Medicine, UNAM and project PAPIIT-DGAPA IN-229611, UNAM. The Spanish Ministry of Science and Innovation (MICINN, ref. SAF2009-10399) is also gratefully acknowledged for partially supporting this paper. We also appreciate the technical assistance of Enrique Pinzón Estrada.


  1. Arora K, Srivastava AK (2005) Antimalarial efficacy of methylene blue and menadione and their effect on glutathione metabolism of Plasmodium yoelii-infected mice. Parasitol Res 97:521–526PubMedCrossRefGoogle Scholar
  2. Argotte RR, Ramírez AG, Rodríguez GMC et al (2006) Antimalarial 4-phenylcoumarins from the stem bark of Hintonia latiflora. J Nat Prod 69:1442–1444CrossRefGoogle Scholar
  3. Baird JK, Rieckmann KH (2003) Can primaquine therapy for vivax malaria be improved? Trends Parasitol 19(3):115–120PubMedCrossRefGoogle Scholar
  4. Becker DE (2006) Drug therapy in dental practice: general principles. Part 1—pharmacokinetic considerations. Anesth Prog 53:140–146PubMedCrossRefGoogle Scholar
  5. Giha H (2010) Artemisinin derivatves for treatment of uncomplicated Plasmodium falciparum malaria in Sudan: too early for too much hope. Parasitol Res 106:549–552PubMedCrossRefGoogle Scholar
  6. Goulart HR, Kimura EA, Peres VJ et al (2004) Terpenes arrest parasite development and inhibit biosynthesis of isoprenoids in Plasmodium falciparum. Antimicrob Agents Chemoter 48:2502–2509CrossRefGoogle Scholar
  7. Höfle G, Bööhlendorf B, Fecker T, Sasse F, Kunze B (2008) Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin. J Nat Prod 71(11):1967–1969PubMedCrossRefGoogle Scholar
  8. Jensen M, Mehlhorn H (2009) Seventy-five years of Resochin in the fight against malaria. Parasitol Res 105:609–627PubMedCrossRefGoogle Scholar
  9. Kaur K, Jain M, Reddy RP, Jain R (2010) Quinolines and structurally related heterocycles as antimalarials. Eur J Med Chem 45(8):3245–3264PubMedCrossRefGoogle Scholar
  10. Lorke D (1983) A new approach to practical acute toxicity testing. Arch Toxicol 54:275–287PubMedCrossRefGoogle Scholar
  11. Marrero-Ponce Y, Castillo GJ, Olazabal E et al (2004) TOMOCOMD-CARDD, a novel approach for computer-aided ‘rational’ drug design: I theoretical and experimental assessment of a promising method for computational screening and in silico design of new anthelmintic compounds. J of Computer-Aided Mol Des 18:615–634CrossRefGoogle Scholar
  12. Moneriz C, Marín-García P, Bautista JM, Diez A, Puyet A (2011) Parasitostatic effect of maslinic acid. II. Survival increase and immune protection in lethal Plasmodium yoelii-infected mice. Malar J 25:10–103Google Scholar
  13. Montero A, García RN, Marrero-Ponce Y et al (2006) Non-stochastic quadratic fingerprints and LDA-based QSAR models in hit and lead generation through virtual screening: theoretical and experimental assessment of a promising method for the discovery of new antimalarial compounds. Eur J Med Chem 41:483–493CrossRefGoogle Scholar
  14. Muregi FW, Kirira PG, Ishih A (2011) Novel rational drug design strategies with potential to revolutionize malaria chemotherapy. Curr Med Chem 18(1):113–143PubMedCrossRefGoogle Scholar
  15. Murray CJL, Rosenfeld L, Lim SS et al (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379:413–443PubMedCrossRefGoogle Scholar
  16. Peters W, Robinson BL (1992) The chemotherapy of rodent malaria. XLVII. Studies on pyronaridine and other Mannich base antimalarials. Ann Trop Med Parasitol 86(5):455–465PubMedGoogle Scholar
  17. Qiu W-W, Shen Q, Yang F et al (2009) Synthesis and biological evaluation of heterocyclic ring-substituted maslinic acid derivatives as novel inhibitors of protein tyrosine phosphatase. Bioorg Med Chem Lett 19:6618–6622PubMedCrossRefGoogle Scholar
  18. Quéré L, Wenger R, Schramm HJ (1996) Triterpenes as potential dimerization inhibitors of HIV-1 protease. Biochem Biophys Res Commun 227:484–488PubMedCrossRefGoogle Scholar
  19. Rangisetty JB, Gupta CN, Prasad AL et al (2001) Synthesis of new arylaminoquinoxalines and their antimalarial activity in mice. J Pharm Pharmacol 53(10):1409–1413PubMedCrossRefGoogle Scholar
  20. Rivera O, Marrero-Ponce Y, Meneses A et al (2009) Discovery of novel trichomonacidals using lda-driven qsar models and bond-based bilinear indices as molecular descriptors. QSAR Com Sci 1:9–26CrossRefGoogle Scholar
  21. Schlitzer M (2008) Antimalarial drugs—what is in use and what is in the pipeline. Arch Pharm 341:149–163CrossRefGoogle Scholar
  22. Sharma A, Mishra NC (1999) Inhibition of a protein tyrosine kinase activity in Plasmodium falciparum by chloroquine. Indian J Biochem Biophys 36(5):299–304PubMedGoogle Scholar
  23. Turner VP, Brabb T, Pekow C, Vasbinder M (2011) Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci 50(5):600–613PubMedGoogle Scholar
  24. Vega MC, Montero A, Marrero Y et al (2006) New ligand-based approach for the discovery of antitrypanosomal compounds. Bioorg Med Chem Lett 16:1898–1904PubMedCrossRefGoogle Scholar
  25. Zhang Y, Qi J, Li J et al (2012) A new antimalarial antigen produces partial protection against Plasmodium yoelii challenge. Parasitol Res 110:1337–1345PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Norma Rivera
    • 1
  • Yovani Marrero Ponce
    • 2
  • Vicente J. Arán
    • 3
  • Cecilia Martínez
    • 1
  • Filiberto Malagón
    • 1
  1. 1.Laboratorio de Malariología, Departamento de Microbiología y Parasitología, Facultad de MedicinaUniversidad Nacional Autónoma de MéxicoMéxicoMexico
  2. 2.Unit of Computer-Aided Molecular “Biosilico” Discovery and Bioinformatic Research, Faculty of Chemistry-PharmacyUniversidad Central “Marta Abreu” de Las VillasSanta ClaraCuba
  3. 3.Instituto de Química Médica, CSICMadridSpain

Personalised recommendations